Bone Mineral Density in Children with Primary Hyperoxaluria Type I
Overview
Nephrology
Authors
Affiliations
Background: In primary hyperoxaluria type I (PH 1), hepatic overproduction of oxalate leads to its deposition in various organ systems including bone (oxalosis). To evaluate skeletal status non-invasively in PH 1 we measured bone mineral density (BMD).
Methods: Peripheral quantitative computed tomography of the distal radius was performed in 10 children with PH 1 (mean chronological age 9+/-3.1, mean skeletal age 8.3+/-3.0 years): seven were on conservative treatment (CT) including one patient after pre-emptive liver transplantation (PH1-CT) and three were studied with end-stage renal disease on peritoneal dialysis (PH1-ESRD).
Results: Mean trabecular bone density (TBD) was significantly increased in PH1-ESRD compared with both age-matched healthy and uraemic controls (65227 vs. 168+/-63 and 256+/-80 mg/cm(3); P<0.002 and P<0.007, respectively), while cortical bone density (CBD) was elevated to a lesser degree (517+/-23 vs. 348+/-81 vs. 385+/-113 mg/cm(3); P<0.02 and P<0.04, respectively). In PH 1, CBD and, even more so, TBD were significantly correlated with serum creatinine (r=0.91 and r=0.96, P<0.0001, respectively) and plasma oxalate levels (r=0.86 and r=0.94, P<0.001 and P<0.0001, respectively). In children with PH 1 and normal glomerular function, both CBD and TBD were comparable with healthy controls.
Conclusion: These preliminary data suggest that in PH 1 BMD is significantly increased in ESRD, probably due to oxalate disposal. Measurement of BMD may be a valuable and non-invasive tool in determining and monitoring oxalate burden in this disorder.
Buscher R, Pape L, Buscher A Front Pediatr. 2024; 12:1353880.
PMID: 38455394 PMC: 10917879. DOI: 10.3389/fped.2024.1353880.
Merz L, Born M, Kukuk G, Sprinkart A, Becker I, Martin-Higueras C Pediatr Nephrol. 2022; 38(7):2083-2092.
PMID: 36472654 DOI: 10.1007/s00467-022-05836-3.
Halfon M, Cochat P, Kissling S, Dattner N, de Leval L, Fakhouri F JIMD Rep. 2021; 62(1):6-8.
PMID: 34765391 PMC: 8574174. DOI: 10.1002/jmd2.12246.
Bone impairment in primary hyperoxaluria: a review.
Bacchetta J, Boivin G, Cochat P Pediatr Nephrol. 2015; 31(1):1-6.
PMID: 25631241 DOI: 10.1007/s00467-015-3048-z.
Update on oxalate crystal disease.
Lorenz E, Michet C, Milliner D, Lieske J Curr Rheumatol Rep. 2013; 15(7):340.
PMID: 23666469 PMC: 3710657. DOI: 10.1007/s11926-013-0340-4.